Key Highlights:,Gilead Sciences successfully raises $3.5 billion through a public offering of senior unsecured notes.,Debt ...

Citi initiated coverage of Gilead (GILD) with a Buy rating and $125 price target The firm says that despite the stock’s near-term ...

(RTTNews) - Gilead Sciences Inc. (GILD) announced the pricing of senior unsecured notes in an aggregate principal amount of $3.5 billion, in an underwritten, registered public offering, consisting of ...

Gilead (GILD) reported positive results from a pivotal Phase 3 study of its twice-yearly HIV prevention treatment lenacapavir ...

Democratic Party leaders and their donors bear responsibility for the increasingly widespread view of trans rights as ...

Investors looking for stocks in the Medical - Biomedical and Genetics sector might want to consider either Gilead Sciences (GILD) or Vertex Pharmaceuticals (VRTX). But which of these two stocks ...

Reporting in recent days has indicated that the two top contenders to lead the Treasury Department in the second Trump administration are billionaires: hedge fund manager and Trump megadonor Scott ...

Gilead Sciences Inc (NASDAQ:GILD) stock is trading higher on Thursday after the company reported better-than-expected ...

Jacquie Ross, Vice President, Investor Relations at Gilead Sciences Thank you, Rebecca. Just after market closed today, we ...

Research by a team of academics into the effects of long Covid has been described as a ‘model for the future of health ...